Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.US-based Regenerx Biopharmaceuticals has received a patent for treating disorders of the eye with Thymosin Beta 4, including treatment for corneal vacuolization, corneal stromal edema, and healing associated with eye surgery including Lasik and PRK.
Subscribe to our email newsletter
The patent, issued in Australia, covers Thymosin Beta 4, its analogues, isoforms and other derivatives and expires in 2022.
Currently, RegeneRx is developing three product candidates, RGN-137, RGN-259 and RGN-352 for dermal, ophthalmic, and cardiovascular tissue repair, respectively. RegeneRx is also developing RGN-457 for use in pulmonary indications such as cystic fibrosis.